Slabin is a resident at Hebrew SeniorLife in Dedham, where her daughter said performances from volunteer musicians make all ...

In a novel theory, scientists at Arizona State University's Biodesign Institute propose a unifying explanation for the ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzhe ...

A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the two key pathological hallmarks of Alzheimer's—tau protein and beta-amyloid ...

InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has ...

The successful financings come amid a more than two-year stretch when the sector has struggled to attract fresh capital with ...

Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, ...

The class’ availability online through Zoom is a major feature. With how Parkinson’s can affect movement, and the ability to travel not always guaranteed, having access to pivotal information ...

Taking longer to reach the rapid eye movement (REM) stage of sleep could mean you are more likely to develop dementia.

A new study has found that taking longer to reach the rapid eye movement (REM) stage of sleep is linked to a greater risk of ...